Checking the ticker for Green Thumb Industries (GTBIF) feels like watching a high-stakes poker game where the players are half-asleep. As of mid-January 2026, the green thumb stock price is hovering around $8.09 on the OTCQX.
It’s a weird spot to be in.
The stock has been bouncing between a 52-week low of $4.63 and a high of $10.43, yet the "smart money" seems to be waiting for a starter pistol that already fired. Honestly, if you’re looking at just the daily percentage shifts—down 2.18% one day, up 4% the next—you’re basically staring at noise. The real movement is happening under the surface, driven by a mix of federal executive orders and some pretty aggressive corporate reshuffling that hasn't fully "priced in" yet.
The Trump Executive Order and the $8 Pivot
Late in December 2025, the cannabis world got a jolt. President Trump signed an executive order directing the Attorney General to finalize the rescheduling of marijuana from Schedule I to Schedule III.
This isn't just bureaucratic fluff.
For a company like Green Thumb, Schedule III is the "Golden Ticket" because of something called Section 280E. Right now, cannabis companies are taxed on gross profit because they aren't allowed to deduct normal business expenses—think rent, electricity, or even paperclips—because they're technically "trafficking" a Schedule I drug.
Moving to Schedule III deletes that tax penalty. Suddenly, Green Thumb's cash flow looks completely different. We’re talking about a massive leap in after-tax profitability without the company having to sell a single extra gram of flower.
📖 Related: Reading a Crude Oil Barrel Price Chart Without Losing Your Mind
Investors reacted. We saw the green thumb stock price surge over 8% on the news, but then the classic "sell the rumor, buy the news" fatigue set in. The market is now asking: "Okay, but when does the IRS actually stop sending the bill?"
Why Green Thumb Isn't Your Typical Weed Stock
Most pot stocks are, frankly, a mess. They burn cash like it’s literal weeds. Green Thumb is the weird kid in the class who actually does their homework.
Look at the Q3 2025 numbers. They pulled in $291.4 million in revenue. That’s a 1.6% increase year-over-year. It doesn't sound like "to the moon" growth, but in a market where prices are compressing and competition is getting cutthroat, staying green (pun intended) is a feat.
The Cash Machine
They ended that quarter with $226 million in cash.
Management has been using that pile to buy back their own shares—about $107 million worth at an average price of $7.95. When a CEO like Ben Kovler starts buying back stock, it’s a signal that they think the market is being stupid about the valuation. They even authorized another $50 million for buybacks through September 2026.
The Agrify / RYTHM Pivot
In August 2025, Green Thumb pulled a move that caught a lot of people off guard. They sold the intellectual property for their big brands—RYTHM, Dogwalkers, and Beboe—to Agrify (now rebranding as RYTHM, Inc.) for $50 million.
Wait, why sell your best brands?
👉 See also: Is US Stock Market Open Tomorrow? What to Know for the MLK Holiday Weekend
Because they didn't really "sell" them in the way you’d think. They entered a licensing agreement. Green Thumb still manufactures and sells them, but the move allows them to expand these brands "beyond the dispensary walls," potentially into the hemp-derived THC market. It's a play for national brand dominance while the federal government is still tripping over its own feet regarding interstate commerce.
What Most People Get Wrong About GTBIF
There’s a common misconception that Green Thumb needs full federal legalization to thrive.
Total myth.
Full legalization might actually bring more competition from Big Tobacco or Big Pharma, which could squeeze margins even further. What Green Thumb really needs is "Rescheduling + Banking." If they get the SAFER Banking Act or even just the 280E relief from Schedule III, they become a cash-flow monster.
They already operate 100+ "RISE" dispensaries across 14 states. They are dominant in limited-license states like Illinois and New Jersey. They recently started adult-use sales in Minnesota. They aren't waiting for Uncle Sam to give them permission to be a billion-dollar company; they already are one.
The 2026 Outlook: Slow Build or Speculative Moonshot?
Don't expect the green thumb stock price to hit $50 by Tuesday.
✨ Don't miss: Big Lots in Potsdam NY: What Really Happened to Our Store
The analysts are being cautious. Zacks recently gave them a "Strong Sell" rating, mostly because the broader medical products industry is struggling and the P/E ratio (currently around 47) looks expensive compared to the S&P 500.
But that's a narrow way to look at it.
If you look at the Forward P/E, it’s closer to 25. For a company expected to grow earnings by 12.5% next year, that’s not exactly "bubble" territory. The "slow build" narrative for 2026 is much more realistic. We're looking at a year of:
- Finalizing the Schedule III transition.
- Cleaning up balance sheets.
- Potentially moving from the OTC markets to a major exchange like the NYSE if the regulatory dust settles.
Real World Risk: The Florida Factor
It’s not all sunshine. Florida’s medical market has been feeling some pressure, and Green Thumb has a significant footprint there. If Florida doesn't transition to adult-use successfully or if price compression continues to eat into margins, the retail revenue (which only grew 0.3% in the last reported quarter) could stagnate.
Also, the "grey market" for hemp-derived THC is a massive competitor. Those drinks and gummies you see in gas stations? They’re eating Green Thumb's lunch in certain markets because they don't have the same tax and regulatory burdens.
Actionable Insights for the Savvy Investor
If you're watching the green thumb stock price, stop looking at the 5-minute charts. They’ll drive you crazy. Instead, focus on these specific triggers:
- The February 25, 2026 Earnings Call: This is the big one. Look for updates on the share buyback program and any specific guidance on how 280E relief is being factored into their 2026 tax strategy.
- The Federal Register: Keep an eye on the Attorney General’s office. The moment the Schedule III rescheduling is officially "published," the clock starts on a massive fundamental re-rating of the entire sector.
- Institutional Inflow: Right now, most big banks won't touch weed stocks. If you see headlines about a major custodial bank (like BNY Mellon or State Street) allowing their clients to hold GTBIF, the liquidity floodgates will open.
Green Thumb is a "fundamentals" play in a "hype" industry. They have the cash, they have the licenses, and they have the brands. The stock price is currently a reflection of federal uncertainty, not corporate incompetence.
For those who can stomach the volatility of the OTCQX, the current price represents a company trading at a discount to its potential once the tax handcuffs are finally removed. Just don't expect it to be a smooth ride. It never is in the weed business.